The use of GLP-1 drugs without medical supervision, including those obtained without a valid prescription, carries potential health risks and may not be suitable for every patient, even among those with type 2 diabetes or obesity
Do not restart treatment if acute pancreatitis is confirmed
In the patients described, the rapid decline in kidney function was temporally associated with semaglutide/tirzepatide administration in the absence of another cause such as dehydration, hypotension, or use of NSAIDs or other nephrotoxic medications
doi:10.1101/2024.01.18.24301500 Haran K, Johnson CE, Smith P, et al
They may increase your dose or prescribe an alternative
In phase II clinical trials involving obese individuals, tesofensine showed promising results